Brian Hyett, MD
Internal Medicine · Portsmouth, NHNPI 1972722015
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,997 of the $184,763 with a category attached, or 66.0%. AbbVie accounts for 69.1% of it on its own, with 32 other manufacturers making up the rest. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $374.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$128K
- Celltrion USA Inc.$31K
- Janssen Scientific Affairs, LLC$13K
- Johnson & Johnson$9K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$727
- Takeda Pharmaceuticals U.S.A., Inc.$490
- plus $2K from 27 others
What the payments were for
- Consulting fees$33,35318%
- Speaking & faculty fees$121,99766%
- Travel & lodging$18,32510%
- Food & beverage$10,9806%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 257 | $127,705 |
| Celltrion USA Inc. | 29 | $30,979 |
| Janssen Scientific Affairs, LLC | 11 | $12,994 |
| Johnson & Johnson(2 entities) | 24 | $9,415 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $727 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $490 |
| Pfizer | 15 | $303 |
| Gilead | 9 | $267 |
| Sanofi | 4 | $227 |
| Covidien LP | 2 | $196 |
| Boston Scientific | 3 | $178 |
| Ferring Pharmaceuticals Inc. | 9 | $157 |
| Intercept Pharmaceuticals, Inc. | 5 | $126 |
| QOL Medical, LLC | 3 | $102 |
| Merck | 6 | $97 |
| Organon | 3 | $74 |
| Ironwood Pharmaceuticals, Inc | 4 | $68 |
| UCB, Inc. | 4 | $62 |
| Daiichi Sankyo Inc. | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $57 |
| Lilly USA, LLC | 3 | $57 |
| Boehringer Ingelheim | 2 | $57 |
| Braintree Laboratories, Inc. | 4 | $56 |
| Ardelyx, Inc. | 2 | $55 |
| Amgen | 3 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Bristol Myers Squibb | 1 | $31 |
| Lundbeck LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,763 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 69 | $1,922,209 |
| RinvoqUpadacitinib | 15 | $138,431 |
| LinzessLinaclotide | 108 | $90,449 |
| XifaxanRifaximin | 14 | $72,446 |
| PentasaMesalamine | 21 | $31,622 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 108 | $18,924 |
| Mesalamine | 31 | $16,773 |
| Omeprazole | 430 | $7,191 |
| Dexlansoprazole DrDexlansoprazole | 13 | $5,216 |
| Azathioprine | 29 | $2,947 |
| Famotidine | 198 | $2,906 |
| Pantoprazole Sodium | 128 | $2,617 |
| Esomeprazole Magnesium | 37 | $2,232 |
| Mercaptopurine | 14 | $1,979 |
| Dicyclomine Hcl | 80 | $1,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $9,415 | $1,922,20969 claims |
| AbbVieRinvoq, Linzess | $127,705 | $228,880123 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $727 | $74,19426 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $157 | $18,924108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Portsmouth
- Magued Rizkalla HannaPortsmouth$26K
- Katelyn HansonPortsmouth$1K
- Thomas ClairmontPortsmouth$791
- Myhanh NguyenPortsmouth$620
- Donald RainoneLondonderry$1.9M
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.